Search results for "count"

showing 10 items of 5058 documents

Ultrasonography-guided central venous catheterisation in haematological patients with severe thrombocytopenia

2012

BACKGROUND: Cannulation of the internal jugular vein (CVC) is a blind surface landmark-guided technique that could be potentially dangerous in patients with very low platelet counts. In such patients, ultrasonography (US)-guided CVC may be a valid approach. There is a lack of published data on the efficacy and safety of urgent US-guided CVC performed in haematological patients with severe thrombocytopenia. MATERIALS AND METHODS: We retrospectively studied the safety of urgent CVC procedures in haematological patients including those with severe thrombocytopenia (platelet count <30×10(9)/L). From January 1999 to June 2009, 431 CVC insertional procedures in 431 consecutive patients were evalu…

AdultAged 80 and overMaleCatheterization Central VenousAdolescentOriginal ArticlesMiddle AgedSeverity of Illness IndexThrombocytopeniaSettore MED/15 - Malattie Del SangueSettore MED/18 - Chirurgia Generalecentral venous catheterisation ultrasound Seldinger technique low platelet count haematological malignancyHumansFemaleAgedRetrospective StudiesUltrasonography
researchProduct

A Successful Aging Model Based on Personal Resources, Self-Care, and Life Satisfaction

2021

The most internationally studied models of successful aging defend that there are several pillars for a good aging: absence of disease, good cognitive and physical function, a high commitment and social activity, social capital, personal resources, life satisfaction, and spirituality. This study examines the relationships between personal resources, perceived social support, hope, spirituality, self-care and subjective well-being variables, as bases for a successful aging. One thousand and sixteen community-dwelling Spanish adults, aged 55-92 years, participated in the study. Information on variables assessed was collected using self-reported questionnaires. Confirmatory Factor Analyses and…

AdultAging050109 social psychologyPersonal SatisfactionDiseaseEducationDevelopmental psychologySocial supportSurveys and Questionnaires0502 economics and businessSpiritualityHumansSpirituality0501 psychology and cognitive sciencesSubjective well-beingGeneral PsychologySuccessful aging05 social sciencesSocial SupportLife satisfactionCognitionConscientiousnessSelf CareBusiness Management and Accounting (miscellaneous)sense organsPsychology050203 business & managementThe Journal of Psychology
researchProduct

15-Lipoxygenase expression and 15(S)-hydroxyeicoisatetraenoic acid release and reincorporation in induced sputum of asthmatic subjects

2000

Recent evidence shows that 15(S)-hydroxy-eicoisatetraenoic acid (15[S]-HETE) can be released and rapidly reincorporated into cellular lipids. These mechanisms exert several immunoregulatory functions that may be relevant in airway inflammation.Our purpose was to evaluate the levels of both soluble and cell-associated 15(S)-HETE and to examine 15-lipoxygenase (15-LO) messenger RNA (mRNA) expression in sputum samples obtained from 10 control and 18 asthmatic subjects.Levels of 15(S)-HETE were measured by reverse-phase HPLC separation followed by RIA in supernatants and in cell membrane-extracted phospholipids after acid hydrolysis. 15-LO mRNA was evaluated by primed in situ hybridization (PRI…

AdultAllergySputum CytologyImmunologyImmunocytochemistryCell CountIn situ hybridizationLipoxygenasechemistry.chemical_compoundForced Expiratory VolumeHydroxyeicosatetraenoic AcidsmedicineArachidonate 15-LipoxygenaseHumansImmunology and AllergyRNA MessengerSalivaIn Situ HybridizationAgedMessenger RNAbiologySputumMiddle Agedmedicine.diseaseImmunohistochemistryMolecular biologyAsthmaSolubilitychemistryImmunologybiology.proteinSputumlipids (amino acids peptides and proteins)Arachidonic acidmedicine.symptomJournal of Allergy and Clinical Immunology
researchProduct

Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor s…

1997

Fifty-five consecutive patients with metastatic breast cancer (MBC) (n = 57) were treated with a combination of levofolinic acid (I-FA) 100 mg/m2 plus 5-fluorouracil (5-FU) 340 mg/m2 i.v. on day 1-3, cyclophosphamide (CTX) 600 mg/m2 i.v. on day 1 and mitoxantrone (DHAD) 12 mg/m2 i.v. on day 1. DHAD dose was progressively escalated by 2 mg/m2/cycle up to 18 mg/m2 in the absence of dose-limiting toxicities. Granulocyte colony stimulating factor (G-CSF) was given s.c. in order to prevent neutropenia. DHAD dosage could be increased to 18 mg/m2 in 66 out of 317 cycles of chemotherapy (21%). In most patients the dose-limiting toxicity was represented by myelosuppression. A statistically significa…

AdultAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentAntidotesLeucovorinAntineoplastic AgentsBreast NeoplasmsPharmacologyNeutropeniaGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansMedicinePharmacology (medical)Antineoplastic Agents AlkylatingCyclophosphamideAgedPharmacologyMitoxantroneChemotherapybusiness.industryMiddle Agedmedicine.diseaseMetastatic breast cancerGranulocyte colony-stimulating factorItalyOncologyToxicityAbsolute neutrophil countFemaleFluorouracilMitoxantronebusinessmedicine.drugAnti-Cancer Drugs
researchProduct

Qualitative variations in delay discounting: A brief review and future directions.

2022

The discounting paradigm has been challenged by an increasing number of studies presenting qualitative variations in the individual discount function. Particularly, the subjective value of a loss does not necessarily systematically decrease with delay to the outcome. Qualitative variation refers to variations in shape rather than steepness of the discount function, such as positive discounting, zero discounting, unsystematic discounting, and negative discounting. Data from three previous studies were analysed in terms of qualitative variations observed in delay discounting patterns. Attention was also given to methods used and to the relationship between the results from the various levels …

AdultBehavioral NeuroscienceAdolescentDelay DiscountingRewardVDP::Samfunnsvitenskap: 200::Psykologi: 260HumansAnimal Science and ZoologyGeneral MedicineBehavioural processes
researchProduct

Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation.

2006

Three commercial systems for whole blood separation were compared to obtain the buffy coat composed of platelet-rich plasma (BC-PRP) and leucocytes . These samples of the buffy coat were used to make a platelet gel (PG), which was used to measure platelet growth factor (PGF) release, to perform a white blood cell (WBC) count and to measure myeloperoxidase (MPO) release from WBCs. Aliquots of whole blood obtained from ten volunteers were distributed either to a blood cell separator (The Electa Cell-Separator (TM), E-CS) or to a tabletop centrifuge (Gravitational Platelet Sequestration System (TM), GPS) to prepare the BC-PRP. The third system combines the BC-PRP production by E-CS with a micr…

AdultBlood PlateletsBuffy coatFibrin Tissue AdhesiveBlood cellTransforming Growth Factor beta1Blood Transfusion AutologousLeukocyte CountThrombinTransforming Growth Factor betaWhite blood cellmedicineLeukocytesHumansPlateletPlatelet activationWhole bloodPeroxidasePlatelet-Derived Growth FactorWound HealingChromatographybiologyChemistryHematologyPlatelet Activationmedicine.anatomical_structureBiochemistryMyeloperoxidasebiology.proteinBlood Component RemovalGelsmedicine.drugTransfusion medicine (Oxford, England)
researchProduct

Curasan PRP kit vs. PCCS PRP system

2002

An important reason to improve methods of isolating platelet-rich plasma (PRP) is the potential use of autologous thrombocyte growth factors. In addition to discontinuous cell separation, two methods for extracting PRP that can be performed directly by the surgeon are now available. This study compared the suitability of these two methods for the preparation of PRP. Whole blood was drawn from 47 healthy donors (18 men, 29 women) aged 20-59 years (mean 29.9, SD 7.7). For each donor, PRP was separated by the PCCS method (PCCS Kit, 3i Implant Innovations, Palm Beach Gardens, FL, USA) and by the Curasan method (analogous to the PRP kit, Curasan, Kleinostheim, Germany). Thrombocyte counts differ…

AdultBlood PlateletsMaleMatched Pair AnalysisMatched-Pair AnalysisStatistics as TopicEfficiencyBuffy coatBiologyStatistics NonparametricInjectionsAndrologySex FactorsSex factorsThrombocyte countCatheterization PeripheralCell separationHumansPlateletGrowth SubstancesWhole bloodPlatelet CountSyringesPlateletpheresisAge FactorsAnticoagulantsEquipment DesignMiddle AgedNeedlesPlatelet-rich plasmaImmunologyFemaleOral SurgeryClinical Oral Implants Research
researchProduct

Clinical Features And Course Of Refractory Anemia With Ring Sideroblasts Associated With Marked Thrombocytosis

2012

Background Refractory anemia with ring sideroblasts associated with marked thrombocytosis was proposed as a provisional entity in the 2001 World Health Organization classification of myeloid neoplasms and also in the 2008 version, but its existence as a single entity is contested. We wish to define the clinical features of this rare myelodysplastic/myeloproliferative neoplasm and to compare its clinical outcome with that of refractory anemia with ring sideroblasts and essential thrombocythemia. Design and Methods We conducted a collaborative retrospective study across Europe. Our database included 200 patients diagnosed with refractory anemia with ring sideroblasts and marked thrombocytosis…

AdultBlood PlateletsMalemedicine.medical_specialtyAdolescentAnemiaAnèmiaRefractory anemia with ringed sideroblastsLower riskGastroenterologyRisk FactorsInternal medicinehemic and lymphatic diseasesmedicineHumansMyeloproliferative neoplasmSurvival analysisAgedRetrospective StudiesTumorsAged 80 and overThrombocytosisThrombocytosisPlatelet CountEssential thrombocythemiabusiness.industryAnemia RefractoryAnemiaHematologyJanus Kinase 2Middle Agedmedicine.diseaseSurvival AnalysisAnemia SideroblasticSurgeryEuropeRefractory anemia with ring sideroblastsMutationFemaleOriginal Articles and Brief ReportsbusinessThrombocythemia Essential
researchProduct

The Association between Peripheral Blood Cells and the Frailty Syndrome in Patients with Cardiovascular Diseases

2020

Background: Frailty syndrome is characterized by multisystem dysregulation frequently found in older individuals or even in younger patients with chronic disabling diseases such as cardiovascular diseases. Objective: To determine whether peripheral blood cell count, and its subpopulations, red blood cell and platelets, morphology and different ratios (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and red blood distribution width-to-platelet ratio) are associated with cardiac frail patients, and through this to improve the prediction of frailty status in patients with cardiovascular diseases. Methods: An observational, retrospective, cohort study enrolling 179 patients with c…

AdultBlood PlateletsMalemedicine.medical_specialtyErythrocytesEndocrinology Diabetes and MetabolismFrailty syndromeperipheral blood countmalnutritionDiseaseArticleCohort StudiesYoung Adultneutrophil-to-lymphocyte ratioInternal medicinemedicineHumansImmunology and AllergyPeripheral blood cellNeutrophil to lymphocyte ratiowhite blood countAgedRetrospective StudiesAged 80 and overFrailtyReceiver operating characteristicred cell distribution width-to-platelet ratiobusiness.industryRed blood cell distribution widthMiddle Agedmedicine.diseaseplatelet-to-lymphocyte ratioCardiovascular diseasesCohortLeukocytes MononuclearFemalered blood cell distribution widthbusinessCohort studyEndocrine, Metabolic &amp; Immune Disorders - Drug Targets
researchProduct

Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy.

1991

A phase I clinical trial was conducted with recombinant human tumour necrosis factor alpha (rhTNF-alpha) in 62 patients with advanced malignancy refractory to previous standard therapy. rhTNF-alpha was given as a 30 min infusion twice a day at 6 h intervals. A total of 10 different dose levels was escalated in cohorts of 6 patients ranging from 2.5 to 200 micrograms/m2 twice a day for 5 days every second week for a total of 8 weeks followed by a 4-week observation period. Major side-effects of TNF-alpha therapy, seen in almost all patients studied, were fever and chills. As dose-limiting side-effects hypotension and liver toxicity were recorded in 4 of 5 patients treated with 200 micrograms…

AdultBlood PlateletsMalemedicine.medical_specialtyNecrosisAdolescentFeverPhases of clinical researchBlood PressureMalignancyGastroenterologyHemoglobinsLeukocyte CountPharmacokineticsRefractoryInternal medicineNeoplasmsmedicineLeukocytesHumansAgedbiologyDose-Response Relationship Drugbusiness.industryPlatelet CountTumor Necrosis Factor-alphaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryOncologybiology.proteinDrug EvaluationTumor necrosis factor alphaChillsFemaleAntibodymedicine.symptombusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct